# Qurient Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qurient-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Seongnam, South Korea
- Website: www.qurient.com
- Total disclosed funding: $22M
- Latest round: Series B (Jun 11, 2014)
- Investors on record: 9

## About

Based in Seongnam, South Korea, and established in 2008, Qurient Therapeutics operates as a clinical-stage biopharmaceutical company that develops novel therapeutics for oncology and inflammatory diseases. In April 2025, DongKoo Bio&Pharma acquired 1.34 million shares in Qurient Therapeutics at KRW 5,952 apiece for KRW 8 billion, in a PIPE transaction.

## Funding rounds

- Series B, Jun 11, 2014, $15M — SBI Investment Korea, Korea Development Bank, LB Investment, KB Investment, SL Investment, Korea Investment Partners, KDB Capital
- Series A, May 28, 2013, $6.4M — Novartis Venture Fund, Atinum Investment

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A
- SBI Investment Korea (https://capitalatlas.ai/funds/sbi-investment-korea) — Series B
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series B